4Ridker PM. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation, 2001,103:1813-1818.
5Freeman DJ, Norrie J, Caslake MJ, et al. C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes, 2002,51:1596-1600.
6Devaraj S, Xu DY, Jialal I. C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis. Circulation, 2003,107:398-404.
7Esposito K, Pontillo A, Di Palo C, et al. Effect of weight loss and lifestyle changes on vascular inflammatory marker obese women: a randomized trial. JAMA, 2003,289:1799-1804.
8Mojiminiyi OA, Abdella N, Moussa MA, et al. Association of C-reactive protein with coronary heart diaease risk factors in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract,2002,58:37-44.
9World Health Organization.Definition,diagnosis and classification of diabetes mellitus and its complications:report a WHO consultation.Geneva,World Health Organization,1999.
10Pickup JC,Mattock MB,Chusney GD,et al.NIDDM as a disease of the innate immune system:association of acute phase reactants and interleukin-6 with metabolic syndrome X.Diabetologia,1997,40:1286-1292.
4Mojiminiyi OA,Abdella N,Moussa MA,et al.Asssociation of C reative pritein with coronary heart disease risk factors in patients with type 2 diabetes mellitus[J].Diabetes Res Clin Pract,2002,58:37-44.
5Pradham AD,lanson JE,Rifai N,et al.C-reactive protein,interleukin 6,and risk of developing type 2 mellitus[J].JAMA,2001,286:327-334.
6崔公让,谭鸿雁.闭塞性动脉硬化症.北京:人民军医出版社,2000:137-140.
7Murabito J M, Evans J C, Larson M G, et al. The ankle-brachial index in the elderly and risk of stroke, coronary disease, and death: the Framingham Study. Arch Intern Med, 2003, 163(16):1939-1942.
8De Graft J G, Ubbink D T, Legemate D A, et al. Interobserver and intraobserve reproducibility of peripheral blood and oxygen pressure measurements in the assessment of lower sxtremity arterial disease. J Vasc Surg, 2001, 33(5):1033-1040.
9Rossi M, Carpi A. Skin microcirculation in peripheral arterial oblit- erative diseasel. Biomed Pharmacother, 2004, 58($):427-431.
10Erbacig A B, Tarakcioglu M, Coskum Y, et ol. Mediators of inflam- mation in children with ldiabetes mellitus: cytokines in type diabet- ic children. J Clin Biochem, 2001, 34(8):645-650.
